Circulation Journal Official Journal of the Japanese Circulation Society http://www. j-circ.or.jp iabetic nephropathy ranks as the leading etiology of end-stage renal disease (ESRD) requiring hemodialysis. 1 Cardiovascular complications largely account for the morbidity and mortality among such patients. 2 More than the most common cardiovascular alteration in ESRD, left ventricular (LV) hypertrophy is also an independent risk factor for survival. 3 As is well known, patients with diabetes mellitus (DM) are more prone to LV hypertrophy, coronary heart disease and impaired LV function. 4 As a distinguishing feature of the disease, diabetic cardiomyopathy is characterized by chronic inflammation, myocardial damage secondary to a metabolic insult, reactive hypertrophy and intermediary fibrosis, structural and functional changes of the small coronary vessels, interference with the management of the metabolic cardiovascular load, and cardiac autonomic neuropathy leading to heart failure. 5-8
iabetic nephropathy ranks as the leading etiology of end-stage renal disease (ESRD) requiring hemodialysis. 1 Cardiovascular complications largely account for the morbidity and mortality among such patients. 2 More than the most common cardiovascular alteration in ESRD, left ventricular (LV) hypertrophy is also an independent risk factor for survival. 3 As is well known, patients with diabetes mellitus (DM) are more prone to LV hypertrophy, coronary heart disease and impaired LV function. 4 As a distinguishing feature of the disease, diabetic cardiomyopathy is characterized by chronic inflammation, myocardial damage secondary to a metabolic insult, reactive hypertrophy and intermediary fibrosis, structural and functional changes of the small coronary vessels, interference with the management of the metabolic cardiovascular load, and cardiac autonomic neuropathy leading to heart failure. [5] [6] [7] [8] Altered cardiac structure and function are commonly found in asymptomatic patients with type 2 DM, even in the absence of hypertension and coronary artery disease. Echocardiography, an excellent non-invasive and imaging modality, defines cardiac structure and function. Early studies showed that half of the diabetic patients with decreased myocardial diastolic function remained undiagnosed on conventional echocardiography. 9 This inability is attributed to echocardiographic subestimation of the degree of diastolic dysfunction of 60% in subjects with normal arterial blood pressure. Under-diagnosis of the diastolic dysfunction may also occur in ESRD patients on maintenance hemodialysis with DM. Recent studies using tissue Doppler imaging (TDI) have contributed to the evaluation of diastolic function. 10- 16 Although TDI may identify myocardial dysfunction in patients with ESRD or DM, 17, 18 whether TDI can facilitate the early detection of advanced LV diastolic dysfunction in ESRD patients with DM remains unclear and has been seldom addressed. We hypothesized that Advanced Diastolic Failure in Diabetic Uremia ESRD patients with DM may have early and advanced LV diastolic dysfunction. Additionally, worsening diabetic cardiomyopathy causes increasing LV filling pressure. 19 Therefore, the aim of this study was to use TDI to determine whether ESRD patients with DM and normal LV systolic function have advanced LV diastolic dysfunction.
Methods

Subjects
A total of 101 ESRD patients having undergone maintenance hemodialysis for at least 6 months at Chang Gung Memorial Hospital, and who fulfilled the inclusion criteria, were enrolled consecutively in this study. Exclusion criteria included atrial fibrillation, LV ejection fraction (LVEF) <50%, moderate to severe valvular disease, pericardial disease, restrictive cardiomyopathy, and inadequate echocardiographic imaging. The patients were assigned to 2 groups based on the presence of type 2 DM. DM was defined as fasting glucose ≥7.0 mmol/L or use of insulin or oral hypoglycemic therapy. Insulin therapy was used in the majority of the subjects. The oral hypoglycemic agent with glipizide was chosen for an adjunct. Mean reported duration of DM was 6.5 years. The type 2 DM group consisted of 34 patients while non-DM group consisted of 67 patients. All patients underwent routine hemodialysis 3 times weekly.
All baseline characteristics and biochemical analyses were recorded before the study. Blood samples were obtained just before initiation of hemodialysis. Another sample was obtained to determine the blood urea level and calculate the urea reduction ratio after hemodialysis. The urea reduction ratios exceeded 75% in all patients. Echocardiography was performed within 20-24 h after the last hemodialysis on the day between dialysis sessions, mid-week. The interval between hemodialysis and echocardiography in each subject was also recorded. The study protocol was reviewed and received approval from the institutional review board. Informed written consent was obtained from each patient before participation in the study.
Conventional Echocardiography
Transthoracic echocardiography was performed using commercially available ultrasound equipment (Vivid 7, GE Vingmed, Horten, Norway) with a 3.5-MHz transducer. Left atrial, aortic and LV diameters and wall thickness were determined from 2-D targeted M-mode echocardiography based on the criteria of the American Society of Echocardiography. 20 LV end-diastolic, end-systolic volumes and LVEF were calculated using a modified Simpson biplane method. LV mass was then calculated based on the area-length formula. 20 Next, LV mass index was calculated as LV mass/body surface area. Relative wall thickness was calculated as the ratio of (2×LVPWd)/ LVEDD, where LVPWd is posterior wall thickness at end diastole, and LVEDD is LV end diastolic internal diameter. Left atrial volume and index were also determined by the arealength method. 20 Mitral flow velocities were recorded via a pulsed-wave Doppler with the sample volume placed at the tip of the mitral valve in the apical 4-chamber view. The mitral inflow velocity curve yielded the following measurements: peak mitral inflow velocity at early (E) and late (A) diastole, and deceleration time of E. Isovolumetric contraction time (IVCT), isovolumetric relaxation time (IVRT) and ejection time (ET) were also measured; myocardial performance index (MPI) was subsequently created according to Tei's method. 21 MPI is expressed as (IVCT+IVRT)/ET. Next, stroke volume and cardiac output were also calculated; cardiac index was obtained by dividing cardiac output by body surface area.
Pulsed-Wave TDI
Pulsed-wave TDI of the mitral annulus was obtained from the apical 4-chamber view immediately after conventional echocardiography. A 2-mm sample volume was placed sequentially at the septal and lateral annulus. The peak systolic (s'), early (e') and late (a') diastolic velocities were then analyzed. Next a combination of transmitral flow velocity with annular velocity (E/e') was calculated to evaluate and estimate LV filling pressures. 11 Assessing the LV diastolic function is an integral aspect of 2-D, Doppler, and tissue Doppler echocardiography according to the guidelines and standards of American Society of Echocardiography. 22 Based on methods described by Gaibazzi et al, 23 the MPI obtained from pulsed-wave TDI (MPIm) was defined as (IVCTm+IVRTm)/ETm, where IVRTm, IVCTm and ETm were measured on pulsed-wave TDI. These variables were analyzed individually, as the average of the septal and lateral annulus. At least 3 end-expiratory beats were measured, and the average was taken.
Measurement Reproducibility
In the first 12 patients, conventional Doppler echocardiographic and TDI parameters from individual regions were measured by 2 independent observers (K.-C.H and C.-H.L) for interobserver variability and by the same observer on 2 separate occasions for intra-observer variability. Variability was determined as the difference between the 2 sets of measurements divided by the mean of the measurements, expressed as a percentage. All data were presented to the observers in a blind manner; they were completely independent of each other. Intra-observer variability and differences were 3.9±3.8% and 3.5±3.5 cm/s for E, 4.5±4.9% and 4.9±5.3 cm/s for A, 3.7±4.5% and 0.3±0.4 cm/s for s', 3.9±4.0% and 0.3±0.3 cm/s for e', and 3.9±3.9% and 0.4±0.4 cm/s for a', respectively. Inter-observer variability and differences were 5.4±5.5% and 4.9±5.0 cm/s for E, 5.9±5.7% and 6.4±6.2 cm/s for A, 5.3±5.1% and 0.4±0.4 cm/s for s', 5.6±5.7% and 0.4±0.4 cm/s for e', and 6.0±5.8% and 0.6±0.6 cm/s for a', respectively.
Statistical Analysis
Continuous variables are expressed as mean ± SD, while categorical variables are expressed as absolute number (percentage). All variables were tested for normal distribution using the Kolmogorov-Smirnov test. The difference of continuous variables between the 2 groups was then tested using unpaired t-test or Mann-Whitney U-test, and chi-squared test when appropriate. Univariate associations between E/e' and the clinical variables were evaluated using the Pearson's (2 interval or ratio variables) or point biserial (when 1 variable is the interval/ratio and the second is dichotomous) correlation coefficients. Multivariate associations between E/e' and the clinical variables were identified on multiple linear regression using variables that reached significance (P<0.1) in the previous unadjusted analysis and other potential confounders' factors 24 as covariates for the 101 patients.
P<0.05 was considered statistically significant. SPSS version 17.0 for Windows (SPSS, Chicago, IL, USA) was used for data analysis. Table 1 lists the subject clinical characteristics. Both groups did not differ with respect to age, hemodialysis duration, in-HUNG KC et al.
Results
Patient Characteristics
terval between hemodialysis and echocardiography, gender and prevalence of hypertension or coronary heart disease. The type 2 DM group had a slightly higher heart rate, systolic blood pressure, and body mass index than the non-DM group. Additionally, the 2 groups were compatible in terms of medications, including angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, β-blockers, calcium channel blockers and diuretics. Table 2 lists the biochemistry results. Although both groups did not significantly differ in terms of hemoglobin, hematocrit, urea, urea reduction ratio, creatinine, electrolytes and albumin, the fasting blood glucose, glycated hemoglobin, cholesterol and triglyceride of the type 2 DM group were significantly greater than those of the non-DM group. Table 3 lists the conventional echocardiographic parameters. The 2 groups did not significantly differ in LV size, LV mass and Doppler parameters, thus reflecting systolic and diastolic function among the 2 groups. The type 2 DM group, however, had a dilated left atrium with an increased left atrial volume index, thick interventricular septum and high relative wall thickness. Additionally, both groups did not differ in MPI. Table 4 lists the TDI parameters. Although both groups were similar in terms of s' of the septal and average of mitral annuli, the type 2 DM group had a lower s' of lateral annulus. The type 2 DM group also had a significantly lower e' on both sides of the annuli than the non-DM group (all P<0.03), but the 2 groups did not significantly differ in a'. Also, the type 2 DM group had low septal and average e'/a' ratios (P<0.02). Moreover, the type 2 DM group had a higher estimated LV diastolic filling pressure as indicated by E/e' at both mitral annuli (septal 16.7±5.7 vs. 14.1±4.5, P=0.017; lateral 12.3±3.6 vs. 10.7±3.2, P=0.026; average 14.5±4.4 vs. 12.4±3.5, P=0.011) than the Data given as mean ± SD or n (%). ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blockers; BMI, body mass index; CCB, calcium channel blockers; CHD, coronary heart disease; DBP, diastolic blood pressure; DM, diabetes mellitus; ESRD, end-stage renal disease; HD, hemodialysis; HR, heart rate; NS, not significant; SBP, systolic blood pressure. 
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Discussion
This study demonstrates that, in ESRD patients with type 2 DM undergoing hemodialysis, LV diastolic dysfunction and elevated estimated LV diastolic filling pressure are obvious. Exactly how the etiologies in ESRD patients differ according to DM on TDI, however, has seldom been addressed. Additionally, the previous study was relatively small. 25 To our knowledge, the present study is the first to use pulsed-wave TDI to directly compare echocardiographic differences between ESRD patients with type 2 DM and those without DM on maintenance hemodialysis in a relatively large cohort study. Interestingly, ESRD patients with DM had a more pronounced diastolic dysfunction than the non-DM group, as evidenced by a significantly lower e' and higher E/e', regardless of the LV mass. By integrating conventional and TDI echocardiography, this study investigated early and advanced diastolic dysfunction in ESRD patients with DM. Additionally, these findings are critical not only in routine early clinical practice of TDI echocardiography, but also in providing more precise and effective therapies at much earlier stages of the disease. For DM patients without overt evidence of heart disease, several studies have examined the effectiveness of abnormal diastolic parameters of TDI, suggesting underlying disturbances of compliance or relaxation. 18,26, 27 Nardi et al evaluated how type 2 DM affected LV geometry and diastolic function in 288 hypertensive patients with chronic kidney disease. 26 They found that DM together with renal dysfunction was associated with a worse diastolic function with significantly low e', high E/e' and left atrial volume index. The present study, which focused on hemodialysis patients, also obtained similar results. Fang et al evaluated 41 patients with DM and 41 matched control subjects with standard echocardiographic rest and dobutamine tissue Doppler-derived indices of systolic and diastolic LV function. 27 That study compared the patients with DM with control subjects at rest, finding an impairment of peak myocardial systolic and early diastolic velocities. The present study also obtained similar results in ESRD patients on hemodialysis therapy. Importantly, this study has demonstrated that ESRD patients with type 2 DM had significantly decreased peak early myocardial diastolic velocities and relatively low peak systolic myocardial velocities, and a significantly elevated E/e'. This elevation may be attributed to excessive diastolic stiffness of the diabetic heart with myocardial fibrosis, which was recognized as the earliest manifestation of LV dysfunction induced by DM. 28, 29 Fang et al, however, also found that myocardial structure and function are altered before the development of myocardial systolic dysfunction in the hearts of patients with DM. 18 Such alterations may be related to the subsequent development of overt diabetic cardiomyopathy. These changes, however, correspond to myocardial fibrosis and are independent of LV hypertrophy. 27 In the present study, the type 2 DM group had more obvious LV diastolic dysfunction but it was also independent of LV mass and LV mass index.
As an effective method for the global estimation of LV performance, MPI is not influenced by the increased left atrial loading pressure often found in the advanced stages of diastolic heart failure, which is a major advantage over classical echocardiographic methods. 21,30 A recent study of patients with DM without macrovascular complications found the index to be significantly and independently associated with diabetic cardiomyopathy. 31 In the present study, however, the ESRD patients did not significantly differ in MPI according to presence of DM. Similarly, both groups did not significantly differ in MPI on TDI. These phenomena may be due to the fact that MPI reflects both systolic and diastolic function in combination, not diastolic function only. Moreover, uremic cardiomyopathy with severe myocyte hypertrophy, disarray and interstitial fibrosis, which induced both advanced systolic and diastolic LV dysfunction in the present subjects, may explain the dilutional effect of systolic dysfunction induced by uremic cardiomyopathy on MPI. 32 Therefore, TDI appears to be a more sensitive approach than MPI to detect LV diastolic dysfunction, not systolic dysfunction, in diabetic ESRD patients.
Finally, according to the present results, left atrial size and volume index correlated well with the E/e'. A previous report also suggested that in subjects without primary atrial pathology or congenital heart or mitral valve disease, increased left atrial size normally implies elevated ventricular filling pressures. 33 With increased stiffness or non-compliance of the LV, left atrial pressure rises to maintain adequate LV filling, and the increased atrial wall tension leads to chamber dilatation as well. Thus, left atrial size and volume increase with severity of diastolic dysfunction.
Study Limitations
Despite its contributions, this study has certain limitations. First, the number of subjects was still relatively small and highly selective. Patients with normal LVEF without structural heart diseases are difficult to identify, especially ESRD patients undergoing hemodialysis. Patients with atrial fibrillation, however, were excluded possibly causing a bias in the results. Still, analyzing the late diastolic velocities in such patients is extremely difficult. Additionally, Doppler techniques are also angle dependent. In this study, these parameters were recorded at an angle of <20° to the Doppler beam, and the longitudinal walls were parallel as much as possible. Furthermore, TDI is not entirely preload independent, 12 but the present patients were investigated during the interdialysis period and lacked a significant volume change during the study period.
Conclusions
In ESRD patients with type 2 DM undergoing hemodialysis, TDI indicated more advanced LV diastolic dysfunction. Also, TDI offers a feasible means of evaluating subclinical alterations of LV function, possibly allowing for the early detection of diabetic heart disease in ESRD patients. a', mitral annular late diastolic peak velocity; E/e', ratio of mitral early peak velocity to annular velocity; e', mitral annular early diastolic peak velocity; e'/a', ratio of early to late diastolic mitral annular velocity; MPIm, MPI of mitral annular velocities; s', mitral annular peak systolic velocity. Other abbreviations as in Tables 1,3. 
